What is CUSIP 39868T105?

CUSIP 39868T105 is the security identifier used in SEC filing datasets for GRTS - Gritstone bio, Inc. - Common Stock, $0.0001 par value per share.

Security Snapshot

Gritstone bio, Inc. - Common Stock, $0.0001 par value per share (GRTS) Institutional Ownership

Q: Who owns GRTS - Gritstone bio, Inc. - Common Stock, $0.0001 par value per share based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 39868T105

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock, $0.0001 par value per share
Symbol: GRTS on Nasdaq
Shares outstanding: 160,529,963

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Filing notes and source

Key facts

GRTS - Gritstone bio, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 39868T105.
13F reference-period holder data is not available.
1 significant owner is listed from Schedule 13D/13G reporting.

Change

Holder data for the Q2 2026 reference period is not available.
Available periods remain in the history table; they do not substitute for the headline period.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

39868T105

13F reference period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

GRTS full holder history Gritstone bio, Inc. SEC filings Gritstone bio, Inc. company facts Gritstone bio, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 39868T105:

Q4 2025 (0 holders) Q3 2025 (1 holder) Q1 2025 (0 holders) Q4 2024 (2 holders) Q3 2024 (55 holders) Q2 2024 (75 holders) Q1 2024 (84 holders) Q4 2023 (88 holders) Q3 2023 (88 holders) Q2 2023 (86 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

GRTS

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Redmile Group, LLC	8.2%		$131,635		13,163,457		Redmile Group, LLC	31 Dec 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Headline period

n/a

Rows shown

1-25 of 29

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	0	$0	-$4,118				0
2025 Q3	7,101	$4,118	+$4,118			$0.58	1
2025 Q1	0	$0	-$773				0
2024 Q4	68,866	$773	-$20,647,950	$0	$0	$0.01	2
2024 Q3	35,628,372	$20,661,928	-$4,308,184	$76,612	$229,325	$0.58	55
2024 Q2	39,212,556	$24,236,603	-$19,716,392	$103,952	$903,244	$0.62	75
2024 Q1	46,863,208	$120,418,820	+$12,687,383	$11,618,970	$2,212,513	$2.57	84
2023 Q4	42,085,723	$85,856,544	-$11,439,635	$212,160	$255,408	$2.04	88
2023 Q3	48,612,900	$83,617,044	-$4,320,891	$99,072	$153,596	$1.72	88
2023 Q2	50,962,397	$99,490,547	+$7,005,623	$65,910	$145,665	$1.95	86
2023 Q1	46,273,450	$128,634,074	+$4,987,326	$234,910	$359,732	$2.78	89
2022 Q4	44,081,544	$152,081,792	+$37,336,995	$150,765	$340,860	$3.45	89
2022 Q3	33,453,341	$85,974,736	-$4,329,965	$217,000	$348,000	$2.57	76
2022 Q2	35,170,357	$85,107,364	-$17,400,543	$299,000	$256,000	$2.42	81
2022 Q1	39,953,370	$164,926,021	-$163,393,442	$1,555,000	$797,000	$4.12	112
2021 Q4	49,079,808	$629,881,488	+$66,066,934	$5,042,000	$7,405,000	$12.86	112
2021 Q3	42,395,927	$458,360,639	+$86,031,471	$7,369,000	$3,649,000	$10.80	90
2021 Q2	34,818,530	$317,890,500	+$6,996,481	$558,000	$531,000	$9.13	99
2021 Q1	34,045,816	$321,066,530	+$42,420,523	$189,000	$383,000	$9.43	96
2020 Q4	31,980,460	$126,010,396	+$37,330,969			$3.94	67
2020 Q3	22,817,492	$60,471,300	-$31,865,053			$2.65	64
2020 Q2	29,186,352	$193,788,948	-$4,335,520			$6.64	79
2020 Q1	29,847,520	$173,782,820	+$3,188,518			$5.82	64
2019 Q4	26,131,590	$234,363,395	+$5,808,914			$8.97	55
2019 Q3	28,600,546	$246,958,867	-$1,661,860			$8.64	61